Surf Therapeutics develops a non-invasive neuromodulation technology positioned within bioelectronic medicine and inflammation-focused therapeutics. The company targets neural pathways involved in immune regulation rather than directly suppressing immune function pharmacologically.

The platform uses focused, broad-beam ultrasound to stimulate peripheral neural circuits associated with the cholinergic anti-inflammatory pathway. This approach aims to modulate neural–immune signaling without implants, surgery, or chronic drug exposure, differentiating it from traditional neuromodulation and biologic therapies.

The technology is being developed for clinical applications in chronic inflammatory and autoimmune conditions, including rheumatoid arthritis and related disorders. Deployment is framed around regulated therapeutic use, with an emphasis on scalable, potentially at-home treatment within formal clinical pathways.